Загрузка...
Ruxolitinib for the management of myelofibrosis: Results of an international physician survey
BACKGROUND: Ruxolitinib is established as treatment for symptomatic myeloproliferative neoplasm (MPN)-associated myelofibrosis. The strict inclusion and exclusion criteria and dose modification rules that applied to the COMFORTI and II studies that led to the licensing of ruxolitinib are not always...
Сохранить в:
| Опубликовано в: : | Leuk Res |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8190959/ https://ncbi.nlm.nih.gov/pubmed/28843161 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2017.08.002 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|